Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
| Autor: | Andrew Hackett, Shinji Furuta, Steve Warrington, Clair Smart, Rajdeep Benning |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Pharmacology Dipeptidyl-Peptidase IV Inhibitors Health Toxicology and Mutagenesis Metabolite Area under the curve General Medicine Dipeptidyl peptidase-4 inhibitor Urine Metabolism Toxicology Biochemistry Excretion chemistry.chemical_compound Pyrimidines chemistry Pharmacokinetics Anagliptin medicine Humans Carbon Radioisotopes Half-Life medicine.drug |
| Zdroj: | Xenobiotica. 43:432-442 |
| ISSN: | 1366-5928 0049-8254 |
| DOI: | 10.3109/00498254.2012.731618 |
| Popis: | 1. The disposition of anagliptin, an orally active, highly selective dipeptidyl peptidase-4 inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men. Almost all the dose (98.2%) was recovered within 168 h: 73.2% in urine and 25.0% in faeces. 2. Anagliptin was rapidly absorbed, with peak plasma concentrations of unchanged drug attained at a mean time of 1.8-h postdose. Mean fraction of the dose absorbed was73%. Unchanged drug and a carboxylate metabolite (M1) were the major components in plasma, accounting for 66.0 and 23.4% of total plasma radioactivity area under the curve, respectively. 3. Anagliptin was incompletely metabolized, with about 50% dose eliminated as unchanged drug (46.6% in urine and 4.1% in faeces). Metabolism to M1 accounted for 29.2% of the dose. No other metabolite accounted for1% dose in excreta or yielded measurable systemic exposure. Terminal half-life of anagliptin and M1 was 4.37 and 9.88 h, respectively. Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|